Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.
You may also be interested in...
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.